Rob Abbott – CEO, ISPOR
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
ABBOTT LABORATORIES is an American-based, global, diversified healthcare firm. Among the world’s largest and most successful corporations, ABBOTT has a presence in more than 160 countries.
Cardiovascular
Diabetes
Diagnostics
Nutrition
Neuromodulation
Pharmaceuticals
Contact:
Address: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064
Tel: (224) 667-6100
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
Marion Allerstorfer, General Manager of Abbott’s diabetes care business in Switzerland and Austria, shares insights from her two-decade career at the company, highlighting Abbott’s strong people-first culture and its ability…
Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of…
General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just…
Mohamed Benali Khoudja, GM for the Francophone Africa cluster at Abbott reveals the rationale behind creating a country cluster, discusses the market for local CMOs in Algeria, and expands on…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie,…
Abbott has been in Indonesia for roughly 42 years already. Over this time, has the affiliate managed to reach a positioning similar to that of the Group globally, or is…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, highlights the achievements of the company’s Rare Humanitarian Program over the last 30 years, bringing treatments to patients in developing…
John M. O’Brien, recently appointed president and CEO of the US National Pharmaceutical Council, calls for innovation in benefit design reform to match the unparalleled speed and ingenuity with which…
In his latest PharmaBoardroom piece, John Singer looks at Biogen’s marketing campaign for its new Alzheimer’s drug, extending and linking the controversy to the grander strategic themes reshaping the ‘drug market’…
Patient advocate and regular PharmaBoardroom contributor Monica Weldon examines how healthcare’s data revolution has thus far largely ignored the patient voice and argues for a more inclusive approach to drive…
The latest from US health care policy, including the Senate budget deal funding for a range of major health care priorities; Biden’s proposed Advanced Research Projects Agency that would reshape…
Writing in the June edition of DIA’s Global Forum magazine, representatives of Japanese pharmaceutical companies with US operations outline how the COVID-19 pandemic affected their ongoing clinical studies. The…
Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual conference, and how the US generics and biosimilars industry might…
With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease (AD) drug since 2003 – PharmaBoardroom has raided…
Taking the example of music’s effect on Alzheimer’s disease patients, John G Singer makes the case for a more holistic approach to healthcare; focusing less on the transformative potential of…
Writing in the May edition of DIA’s Global Forum magazine, Erica Lyons, Sarrit Kovacs, Matthew Kowalik, and Jessica Lee from the Division of Gastroenterology, Office of New Drugs, CDER at…
The day the Biden administration announced its support for the waiver of IP rights for COVID-19 vaccines, Moderna’s stock fell six percent; the day after that, another two percent. However, the Massachusetts-based…
In a shock move, Joe Biden’s administration looks set to support a waiver on intellectual property (IP) protections for COVID-19 vaccines. The decision – which comes amid worrying situations…
See our Cookie Privacy Policy Here
